Taken together, the preclinical study using in vivo mouse model confirms that targeting the newly identified ERβ/TGF‐β1/SMAD3 signals with the FDA‐approved anti‐estrogen ICI182,780 or the selective ERβ antagonist PHTPP could more effectively reduce RCC tumor growth and invasion. This evidence concerns the gene ESR2 and neoplasm.